Observational Study of Meloxicam in Mexican Patients With Rheumatic Diseases

Boehringer Ingelheim22,639 enrolled

Overview

Observational study to evaluate the efficacy and safety of meloxicam (Mobicox®) in Mexican population with rheumatic diseases

Study Type

OBSERVATIONAL

Enrollment

22,639

Conditions

Arthritis, Rheumatoid

Interventions

MeloxicamDRUG

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age of 12 or older and rheumatologic disease Exclusion Criteria: * Hypersensitivity to meloxicam * Hypersensitivity to other Non-steroidal anti-inflammatory drugs (NSAIDS) * History of asthma, angioedema or urticaria secondary to NSAIDS * Pregnancy or lactation * Recent or current history of peptic ulcer disease, severe renal failure and severe hepatic failure

Outcomes

Primary Outcomes

Intensity of symptoms at rest evaluated with a 4-point scale

Time frame: 30 and 90 days

Intensity of symptoms during movement evaluated with a 4-point scale

Time frame: 30 and 90 days

Medical global evaluation on a 4-point scale

Time frame: 30 and 90 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.